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Abstract: Farnesoid X receptor (FXR) and Takeda G-protein coupled receptor 5 (TGR5) are the two
known bile acid (BA) sensitive receptors and are expressed in the intestine and liver as well as in
extra-enterohepatic tissues. The physiological effects of extra-enterohepatic FXR/TRG5 remain unclear.
Further, the extent BAs escape liver reabsorption and how they interact with extra-enterohepatic
FXR/TGR5 is understudied. We investigated if hepatic BA reuptake differed between BAs agonistic
for FXR and TGR5 compared to non-agonists in the rat. Blood was collected from the portal vein
and inferior caval vein from anesthetized rats before and 5, 20, 30, and 40 min post stimulation
with sulfated cholecystokinin-8. Plasma concentrations of 20 different BAs were assessed by liquid
chromatography coupled to mass spectrometry. Total portal vein BA AUC was 3–4 times greater than
in the vena cava inferior (2.7 ± 0.6 vs. 0.7 ± 0.2 mM x min, p < 0.01, n = 8) with total unconjugated
BAs being 2–3-fold higher than total conjugated BAs (AUC 8–10 higher p < 0.05 for both). However,
in both cases, absolute ratios varied greatly among different BAs. The average hepatic reuptake
of BAs agonistic for FXR/TGR5 was similar to non-agonists. However, as the sum of non-agonist
BAs in vena portae was 2–3-fold higher than the sum agonist (p < 0.05), the peripheral BA pool was
composed mostly of non-agonist BAs. We conclude that hepatic BA reuptake varies substantially by
type and does not favor FXR/TGR5 BAs agonists.
Keywords: hepatic bile acid reuptake; bile acid spill over; bile acids in plasma; portal vein versus
periphery; FXR and TGR5 receptors
1. Introduction
Bile acids (BAs) are amphipathic, steroidal fat emulsifiers secreted from the liver and released
from the gallbladder into the intestinal lumen to facilitate lipid absorption (Figure S1). Bile acids
exist in primary or secondary forms. Primary BAs are synthesized in the liver, whereas secondary
BAs result from bacterial metabolism in the lower small intestine and colon. Furthermore, BAs can
be conjugated with either taurine or glycine, which both carry a negative charge at physiologic pH,
forming bile acid salts with increased solubility. In their salt form, BAs emulsify fat and form micelles,
which help solubilizing, transporting, and absorbing the lipase products of dietary lipids. Intestinal
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BAs are efficiently reabsorbed and returned to the liver via the enterohepatic circulation. In the liver,
BAs are taken up, reconjugated, rehydroxylated, and resecreted to the gut (in rats) or directed to the
gallbladder (in mice and humans), for concentration and storage until secretion is warranted [1,2].
Concurrent with their role in fat emulsification, BAs exert endocrine-like signaling activity through
interaction with the two BA-sensitive receptors, the farnesoid X receptor (FXR, a nuclear receptor) and
the Takeda G-protein coupled receptor 5 (TGR5, a cell surface receptor) [3,4], which are both highly
expressed in the intestine and liver (however, for TGR5 only in non-parenchymal liver cells). Here,
they both act to regulate BA abundance [3,4]. Additionally, TGR5 may regulate glucose, lipid and
energy-metabolism [5] by increasing intestinal absorption through stimulation of intestinal secretion
and peristaltic movements [6] and by stimulating the secretion of appetite- and blood-glucose regulating
hormones via activation of basolaterally located TGR5 receptors [7–9]. FXR signaling seems restricted
to regulation of BA synthesis from cholesterol through control of hepatic genes, secretion of BAs
into bile [10,11], and regulation of the expression and secretion of fibroblast growth factor FGF19
(FGF15 in rodents) [12].
FXR and TGR5 are also found in non-enterohepatic tissues. TGR5 expression is high in the
brain, spinal cord, smooth muscle tissue [13–17] and adipocytes, while FXR expression is high in
the spleen, white adipose tissue, pituitary, adrenal gland, the kidneys, and the vasculature [18,19].
The physiological function of TGR5 and FXR in tissues outside the gastrointestinal tract and liver
is not well understood, and it remains elusive to what extent and under which circumstances these
receptors are activated. Hepatic BA reuptake is incomplete, rendering BAs detectable in the systemic
circulation both during fasting and postprandially [20,21]. In the gut lumen and in the draining gut
veins, the portal vein, and the liver, total BA concentrations range from 0.1 to 10 mM, but in the
periphery, total concentrations are within the one to two digit micro molar range [20,21]. However,
total BA concentration does not necessarily reflect potential for activation since some BAs are more
potent agonists (LCA > CDCA > DCA, including glycine and taurine-conjugated isoforms) than others
(CA and UDCA, also including glycine and taurine-conjugated isoforms) with agonistic BAs having
EC50s towards FXR/TGR5 between 1–10 µM [22–26]. Together, the role of BAs as signaling molecules
outside of enterohepatic circulation is unclear. To further our understanding of BA circulation,
we stimulated BA secretion by sulfated CCK-8 in anesthetized rats and assessed concentration and
composition by liquid chromatography coupled mass spectrometry (LCMS) of 20 different BAs in
plasma collected from the portal vein (representing the enterohepatic BA return) and from the inferior
vena cava (representing BAs that escaped liver extraction) (Figure S1). A second, related aim of our
study was to elucidate whether the BA composition in systemic venous blood reflects the composition
of BAs that return from the gastrointestinal tract to the liver.
2. Results
2.1. Total, Total Conjugated, and Total Unconjugated BA Concentrations in the Portal Vein and Vena Cava
Total BA concentration at baseline was 58.9 ± 10.7 µM in vena portae (Figure 1a). As expected, the
concentration in the vena portae was higher than in the vena cava inferior, where the plasma total BA
concentration was 18.2 ± 5.18 µM (p < 0.001, Figure 1a). Overall, total BAs tended (p = 0.13) to increase
around 40 min post CCK stimulation in vena portae, whereas the concentrations in vena cava inferior
did not change (p = 0.47). Total BA AUC values in vena portae were 4 times higher than total BA AUC
in vena cava inferior (p < 0.01, Figure 1a–c). Unconjugated BAs constituted most of the BA pool in
both the portal vein and vena cava inferior. On average, basal unconjugated BAs were approximately
twofold higher in the vena portae compared to the vena cava (36.4 ± 12.1 and 16.8 ± 7.30 µM in the
vena portae and vena cava, respectively (p = 0.19, Figure 1a)). At 40 min, concentrations in vena
portae were 63.7 ± 19.8 µM (p < 0.001, compared to 0 min) and 19.1 ± 6.56 µM in vena cava inferior
(p = 0.70 compared to 0 min, Figure 1a). Total AUC values were approximately three times higher in
vena portae than vena cava inferior (Figure 1d,e, p < 0.01). The concentrations of conjugated total BAs
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at 0 min were 22.5 ± 9.32 µM in vena portae and 1.43 ± 0.57 in vena cava inferior, but neither was
significantly different at 40 min (p > 0.90). Total AUC for conjugated BAs was approximately 10-fold
higher in vena portae than in vena cava inferior (p < 0.05, Figure 1h,i). The concentration ratios at 0 min
and 40 min across the liver of total bile acids, as well as the total conjugated BAs and unconjugated
BAs, did not differ, but the relative extraction (i.e., the amount presumed to be absorbed by the liver) of
conjugated BAs was fivefold higher than the extraction of unconjugated BAs.
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unconjugated, and total conjugated bile acid levels in V. cava compared to V. portae before injection 
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Figure 1. Total, total unconjugated, and total conjugated bile acid. Concentrations are shown at
individ al time points (means ± SEM, µM) and by AUC values from −5 to 40 min (µM × min) as
well as by relative levels (means ) in ve a cava (V. c va) co pared to levels in vena portae
(V. portae). AUC values are presented as box and whisker plots as well as connected individual
AUC-values (µM × min). (a–c): Total bile acids (sum of tota unconjugated and total unconjugated),
(d–f): Total unconjugated bile acids, (g–i): Total conjugated bile acids, (j): Relative levels of total total
unconjugated, and total conjugated bile acid levels in V. cava compared to V. portae before injection of
CCK (sulfated CCK-8) (zero p int, white boxes) and 40 min after injection (black boxes). Z r point was
calculated by taking the averag f −5 and 0 min concentrations. Grey: Vena portae, lack: vena cava.
* p < 0.05, ** p < 0.01, **** p < 0.0001. Statistical significance was tested by paired student t-test. n = 8.
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2.2. Concentrations of Primary BAs in the Portal Vein and Vena Cava
Cholic acid (CA) and tauro (T) cholic acid concentrations were threefold higher in vena portae
compared to chenodeoxy cholic acid (CDCA) and TCDCA. CCK increased the concentration of
CA in vena portae by approximately 50% (p < 0.001) but did not affect TCA, CDCA, or TCDCA
concentrations (p = 0.13–0.99), which in case of CDCA and TCDCA remained low throughout the
experiment (Figure 1 and Table 1). The fractional concentration of individual bile acids in vena cava
inferior compared to respective concentrations in vena portae varied greatly among BAs and was at
0 min: TCA = 0.08 ± 0.03 µM, TCDCA = 0.19 ± 0.03 µM, CA = 0.30 ± 0.03 µM; CDCA = 0.61 ± 0.06 µM.
Fractions did not differ significantly (p = 0.71–0.99) at time 40 min versus 0 min, except for CDCA
which was mildly lower (40 min: 0.40 ± 0.03 µM, p < 0.01) (Figure 1 and Table 1). Concentrations
of glycine-conjugated isoforms of the respective BAs were below quantification limit, except for
glycine-CA which at 40 min was 4.63 ± 1.75 µM in vena portae and 0.97 ± 0.25 µM in vena cava inferior
and did not change significantly throughout the experiment (data not shown).
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Table 1. Bile acids in plasma from vena portae and vena cava inferior.
Plasma from Vena Portae Plasma from Vena Cava Inferior
Bile acid Baseline (µM) 40 min (µM) AUC (µM x min) Baseline (µM) 40 min (µM) AUC (µM x min) Ratio:V. Cava/V. Portae
Collected
Total 58.9 ± 10.7 87.4 ± 25.1 2650 ± 634 18.3 ± 5.18 28.0 ± 8.68 726 ± 231 ** 0.25 ± 0.07 (0 min)0.20 ± 0.03 (40 min)
Total conjugated 22.5 ± 9.32 30.4 ± 10.1 899 ± 317 1.43 ± 0.57 2.18 ± 0.91 92.4 ± 45.1 * 0.08 ± 0.03 (0 min)0.07 ± 0.02 (40 min)
Total unconjugated 36.4 ± 12.1 63.7 ± 19.8 1752 ± 535 16.8 ± 7.30 19.1 ± 6.56 636 ± 222 ** 0.35 ± 0.05 (0 min)0.29 ± 0.02 (40 min)
Primary BAs
CA 13.6 ± 4.10 21.9 ± 5.87 190 ± 50.4 4.67 ± 1.73 5.54 ± 1.35 658 ± 168 ** 0.30 ± 0.03 (0 min)0.28 ± 0.02 (40 min)
TCA 10.5 ± 4.39 12.6 ± 4.38 404 ± 153 0.56 ± 0.19 0.81 ± 0.32 37.4 ± 17.2 * 0.08 ± 0.03 (0 min)0.07 ± 0.02 (40 min)
CDCA 4.41 ± 2.67 6.50 ± 3.21 186 ± 99.4 2.89 ± 1.18 2.34 ± 1.01 93.3 ± 50.2 0.61 ± 0.06 (0 min)0.43 ± 0.03 (40 min)
TCDCA 2.30 ± 0.91 3.34 ± 0.96 95.1 ± 25.8 0.31 ± 0.08 0.37 ± 0.09 16.0 ± 5.31 ** 0.19 ± 0.03 (0 min)0.13 ± 0.01 (40 min)
Secondary BAs
DCA 2.45 ± 0.85 4.87 ± 1.66 128 ± 43.4 0.97 ± 0.35 1.14 ± 0.35 43.2 ± 12.9 * 0.43 ± 0.03 (0 min)0.33 ± 0.08 (40 min)
TDCA 0.92 ± 0.18 1.34 ± 0.39 39.4 ± 10.5 0.18 ± 0.17 0.20 ± 0.035 8.86 ± 1.20 0.25 ± 0.04 (0 min)0.19 ± 0.03 (40 min)
UDCA 7.02 ± 3.28 15.7 ± 7.60 387 ± 179 5.44 ± 2.89 6.43 ± 3.285 197 ± 91.3 * 0.25 ± 0.04 (0 min)0.19 ± 0.03 (40 min)
TUDCA 1.58 ± 0.81 3.69 ± 1.80 387 ± 179 0.26 ± 0.07 0.40 ± 0.19 197 ± 91.3 0.47 ± 0.13 (0 min)0.39 ± 0.13 (40 min)
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Table 1. Cont.
Plasma from Vena Portae Plasma from Vena Cava Inferior
Bile acid Baseline (µM) 40 min (µM) AUC (µM x min) Baseline (µM) 40 min (µM) AUC (µM x min) Ratio:V. Cava/V. Portae
Murine specific BAs
MCA alpha 1.95 ± 0.87 4.23 ± 1.77 97.4 ± 39.4 0.93 ± 0.44 1.00 ± 0.42 34.8 ± 13.6 * 0.46 ± 0.04 (0 min)0.37 ± 0.06 (40 min)
MCA beta 2.65 ± 0.94 6.42 ± 2.02 144 ± 46.3 1.26 ± 0.49 1.85 ± 0.58 60.0 ± 15.9 * 0.42 ± 0.04 (0 min)0.69 ± 0.37 (40 min)
TMCA alpha 2.01 ± 0.82 2.98 ± 0.91 81.9 ± 25.7 0.29 ± 0.08 0.36 ± 0.10 14.9 ± 5.09 0.25 ± 0.05 (0 min)0.16 ± 0.03 (40 min)
TMCA beta 5.29 ± 2.60 6.52 ± 2.22 203 ± 78.1 0.25 ± 0.07 0.39 ± 0.14 20.7 ± 10.9 ** 0.16 ± 0.06 (0 min)0.08 ± 0.01 (40 min)
TGR5/FXR
Agonists 2.52 ± 0.74 3.75 ± 0.97 112 ± 28.3 1.09 ± 0.48 1.27 ± 0.33 40.4 ± 13.7 ** 0.38 ± 0.04 (0 min)0.25 ± 0.03 (40 min)
Non-agonists 8.73 ± 1.64 12.7 ± 2.85 382 ± 78.6 2.74 ± 0.91 4.03 ± 1.06 110 ± 29.4 *** 0.25 ± 0.03 (0 min)0.31 ± 0.05 (40 min)
Data are shown as mean ± SEM; grey: vena portae, black: vena cava inferior. Concentrations (µM) at baseline (average of −5 and 0 min) and 40 min after injection of CCK-8 are shown.
AUC (µM × min) values were calculated using all time points in the experiment (from −5 to 40 min). AUC ratios between vena cava (V. Cava) and vena portae (V. Portae) were calculated
by normalizing individual concentrations of the respective bile acids in vena portae to the corresponding concentration in vena cava inferior. Following BAs were, based on previous
studies on FXR activation and TGR5 activation [22–26] categorized as FXR and TGR5 agonists: Deoxycholic acid, Chenodeoxycholic acid, Lithocholic acid (both unconjugated and glycine-
and taurine-conjugated isoforms). Cholic acid and Ursodeoxycholic acid were classified as non-agonists based on same studies. Murine specific BAs were not included in the analysis
because of lack of information with regards to agonistic/non-agonistic functions on FXR and TGR5. * p < 0.05, ** p < 0.01, *** p < 0.001. Abbreviations: BA: bile acid, T: Taurine, CA: Cholic
acid, CDCA: Chenodeoxycholic acid, DCA: Deoxycholic acid, MCA: Muricholic acid, UDCA: Ursodeoxycholic acid.
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2.3. Concentrations of Secondary BAs in the Portal Vein and Vena Cava
Concentrations of the secondary BAs DCA, TDCA, ursoDCA (UDCA), and TUDCA were generally
low (<2.5 µM) in vena portae at 0 min, expect for UDCA which was 7.02 ± 3.28 µM (Table 1). In vena
cava inferior, concentrations of DCA, UDCA, and TUDCA at 40 min were 1.5–2-fold higher than at
0 min (p < 0.05, compared to respective basal levels), (whereas TDCA concentrations remained near
the quantification limit (Table 1). AUCs were ~3-fold lower for DCA in vena cava inferior than in vena
portae (p < 0.05) and tended to be lower in vena cava inferior (3–5-fold) for TDCA (p = 0.11), UDCA
(p = 0.08), and TUDCA (p = 0.11) (Table 1). Fractional individual BAs in vena cava inferior compared
to respective concentrations in vena portae were at 0 min: DCA = 0.43 ± 0.03; UDCA = 0.25 ± 0.39;
TDCA = 0.80 ± 0.09; TUDCA = 0.47 ± 0.13). Fractions for the individual BAs did not differ significantly
between times 0 and 40 min (p = 0.23–0.99) (Table 1).
2.4. Concentrations of Murine Specific BAs in the Portal Vein and Vena Cava
Murine CA (MCA) alpha and MCA beta concentration in vena cava inferior was at time 0 min
1.95 ± 0.87 and 2.65 ± 0.94 µM, respectively. Taurine-conjugated forms of these were in vena cava
inferior at same time point 2.01 ± 0.82 µM and 5.29 ± 2.60 µM, respectively. MCA alpha and TMCA
beta concentrations did not change over the time course of the study, but MCA beta and TMCA
alpha were 2–3-fold higher at time point 40 min (p < 0.01) (Table 1). Corresponding concentrations
in vena cava inferior were at time point 0 min and 40 min: MCA alpha: 0 min: 0.93 ± 0.44 µM,
40 min = 1.00 ± 0.42 µM; MCH beta: 0 min = 1.23 ± 0.49 µM, 40 min = 1.85 ± 0.58 µM; TMCA
alpha: 0 min = 0.29 ± 0.08 µM, 40 min = 0.36 ± 0.10 µM; TMCA beta: 0 min = 0.25 ± 0.07 µM,
40 min = 0.39 ± 0.14 µM, i.e., no significant differences between 0 min and 40 min. AUCs in vena
portae were approximately 2-, 3-, 5-, and 8-fold higher in than in vena cava inferior for MCA alpha,
MCA beta, TMCA alpha, and TMCA beta, respectively (p < 0.05, Table 1). Fractional concentration of
individual bile acids in vena cava inferior compared to respective concentrations in vena portae was
not significantly different at time 0 min and 40 min for the individual BAs (p = 0.70–0.88), but varied
among BAs (Table 1). Glycine-conjugated forms of the respective BAs were below quantification limit.
2.5. Concentration of FXR and TGR5 Agonistic BAs in Peripheral Blood is below Activating Concentrations,
and Hepatic Extraction of BAs is Independent of Their Potency and Efficacy towards These Receptors
It is well established that the liver retains a large proportion of BAs from the portal vein [27].
We assessed whether FXR/TGR5 agonistic BAs were preferentially allowed to pass into peripheral
circulation by comparing the concentrations and compositions in the vena portae to those in the
vena cava. BA concentration in the vena cava varied substantially by type of BA. The apparent liver
reabsorption fraction ranged from 10%–45% (Table 1). When stratified into agonists and non-agonist
for FXR/TGR5, the hepatic extraction ratios were similar (Figure 2a,b and Table 1), suggesting that
BA reuptake in the liver is independent of potency towards FXR/TGR5. However, comparing to
observations in the vena portae (Table 1), the mean non-agonist BA concentrations were threefold higher
in vena cava inferior (AUCs: conjugated BAs = 112 ± 28.3 µM/min, non-agonists = 382 ± 78.6 µM/min,
p < 0.01. n = 8, Figure 2a,b and Table 1). The relative level of agonistic and non-agonistic BAs towards
FXR and TGR5 in vena cava inferior compared to vena portae was similar at the individual time points
and over the course of the experiment (mean AUC ratios) (Figure 2e,f, p > 0.05, n = 8).
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Figure 2. FXR and TRG5 activating bile acids and non-activating bile acids. Levels of bile acids
that respectively are agonist and non-agonists for FXR and TGR5 are shown. Following BAs were,
based on previous studies on FXR activation and TGR5 activation [22–26], categorized as FXR and
TGR5 agonists: Deoxycholic acid, Chenodeoxycholic acid, Lithocholic acid (both unconjugated and
glycine- and taurine-conjugated isoforms). Cholic acid and Ursodeoxycholic acid were classified as
non-agonists based on same studies. Murine specific BAs were not included in the analysis because of
lack of information with regards to agonistic/non-agonistic functions on FXR and TGR5. (a,b): Mean
concentration of FXR/TGR5 agonists and non-agonists at individual time points (mean ± SEM, µM)
(µM) in vena portae (a), vena cava inferior (c). (c,d): AUC values (−5 to 40 min) of FXR/TGR5 agonists
and non-agonists (mean values ± SEM) in vena portae (b) and vena cava inferior (d). Individual values
are indicated with dots. (e): Relative level (mean ± SEM) of FXR/TGR5 agonist and non-agonists (conc.
vena cava inferior/conc. Vena portae). (f): Mean bile acid AUC ratio (−5 to 40 min) of FXR/TGR5 agonist
and non-agonists (conc. vena cava inferior/conc. Vena portae) (e). Individual values are indicated with
dots. FXR/TGR5 agonist was defined as chenodeoxycholic acid, taurodeoxycholic acid, deoxycholic
acid, and taurodeoxycholic acid, whereas non-agonist was cholic acid, taurocholic acid, ursocholic acid,
and tauroursocholic acid. Murine-specific BAs (MCA alpha, MCA beta, and taurine-conjugated forms
of these) were not included in the analysis because of lack of information regarding FXR and TGR5
activation. Statistical significance was tested by paired student t-test, ** p < 0.01, *** p < 0.001, n = 8.
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3. Discussion
Compared to the gastrointestinal tract and liver, extra-enterohepatic FXR and TGR5 regulation
has been studied to a limited extent with focus mainly on distribution of tissue expression, not
on ligand concentration. TGR5 expression is high in the brain, spinal cord, smooth muscle tissue,
and adipocytes [13–17], while FXR is expressed highly in the spleen, white adipose tissue, pituitary,
adrenal gland, the kidneys, and the vasculature [18,19]. The extent of receptor activation by specific
BA isoforms in these tissues and the down-stream effects of activation remain largely unknown.
We hypothesized that if BAs act as agonists post liver, hepatic reuptake of potent FXR/TGR5 BAs
agonists would differ from non-agonists. We investigated concentrations of 20 different BAs in rat
plasma collected immediately before liver reuptake (vena portae) and after perfusion through liver
(vena cava inferior).
We and others [28] have shown that human TGR5 is activated with EC50 values of 0.4–10 µM
in the following hierarchy of potencies: lithocholic acid (LCA) > DCA > CDCA, independent of
conjugation, whereas neither CA nor UDCA (both conjugated and unconjugated isoforms) activated
the receptor at concentrations up to 10 µM [22,23]. Human FXR is differentially activated in the
following order of potencies: CDCA > DCA > LCA with EC50 values in the range of 10–100 µM [24–26].
In the case of TGR5, CA and UDCA were poor agonists or did not activate the receptor [24–26].
In humans, fasting total plasma BA-concentrations collected from a peripheral vein are normally in the
single-digit micromolar range and increase by a factor of 2–3 after intake of fat-rich meals [20,29,30].
However, total concentrations do not allow predictions regarding receptor activation, given ligand
specificity. We found that total BA concentrations in vena portae were 4–5 times higher than in
peripheral veins, which is in agreement with other studies in rats, pigs, and monkeys (based on
quantification of total BAs) [31–33]. In humans, the relative hepatic BA reuptake seems to be even
higher, as the total BA concentration in peripheral blood is only 10%–16% of the concentration in the
portal vein [21,31,32]. Whether this difference results from inter-species difference with respect to the
dilution of the splanchnic in to the systemic circulation (the splanchnic bed receives around 1/4 to 1/3 of
the cardiac output) or results from more efficient hepatic reuptake in humans is not well characterized.
We found that the concentration of conjugated BAs in vena cava inferior was as a whole less than
1/10 of the concentration in vena portae, whereas the ratio for unconjugated BAs was around 1/3.
Since measurements were within animals over time, differences in the splanchnic bed–cardiac output
ratio cannot have influenced the measured concentrations, and hepatic reuptake of conjugated BAs
is therefore about three times more efficient than their unconjugated counterparts. The mechanisms
underlying preferential re-uptake of conjugated BAs warrants further investigation but may relate to
differing transport capacities of the primary hepatic transporters (Na+ taurocholate cotransporting
protein) and non-conjugated BAs (organic anion transporting protein family) into the hepatocytes [34].
Furthermore, the variability of reuptake may also be influenced by differences in hydrophobicity with
more hydrophobic BAs more easily diffusing through the plasma membranes, and ultimately into the
liver. In the current study, no clear evidence was found to support this as hydrophobicity (measured
by retention time on a Phenomenex PS C18) did not correlate with hepatic retention; neither in case of
non-conjugated BAs (Pearson correlation = 0.609, p-value = 0.200) nor their corresponding conjugated
forms (Pearson correlation = 0.109, p-value = 0.837). However, since our study was not designed and
powered to address this aspect, future work with expanded sample sizes is needed to appropriately
address this possible explanation. However, as activation of FXR/TGR5 differs among BAs and is
unaffected by conjugation, total concentrations of conjugated and unconjugated BAs provides little
information with regard to potential extra-enterohepatic FXR and TGR5 activation. We therefore
quantified the concentrations of unconjugated and conjugated CA, CDCA, DCA, UDCA, MCA alpha,
and MCA. In the portal plasma, CA and TCA predominated and composed approximately 40% of
the total BA concentration, whereas CDCA and DCA and their taurine-conjugated counterparts each
accounted for only 2%–7%. These ratios are in agreement with another study in rat [35]. In humans,
CA is also the predominant BA in the portal vein, and in contrast to the rat, CDCA is the second-most
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abundant BA and makes up about half the concentration of CA [21]. This species difference may in part
be attributed to Cyp2c70 expression in mice and rats but not humans. Cyp2c70 catalyzes hydroxylation
of CDCA to form the murine specific BAs alpha-MCA [36]. Indeed, the portal concentration of MCA
combined with the concentration of CDCA measured in our study is about half the total concentration
of CA.
Of note, concentrations of different BA specimens in the periphery varied greatly and differed
by almost 50-fold between the most (UDCA) and the least abundant (TDCA) BA. Moreover, the ratio
difference between portal and peripheral concentrations for the quantified BAs varied widely, ranging
from 0.07 µM (TCA) to 0.46 µM (MCA alpha). However, when grouped into agonist for FXR/TGR5
(CDCA, TCDCA, DCA, TDCA) and poor-agonists/non-agonists (CA, TCA, UDCA, TUCDA), average
ratios between concentrations in vena portae and vena cava inferior were similar between groups,
suggesting hepatic reuptake of BAs is regulated by hepatic BA delivery rather than ability to activate
FXR/TGR5. As non-agonists accounted for more than 2/3 of the total BA pool in the portal vein,
peripheral concentrations of non-agonist BAs dominated and the average concentration of agonist
BAs amounted to around 1 µM at baseline and peaked at approximately 1.3 µM. As a reference, EC50
values for these agonists on FXR/TRG5 are 1–10 µM, suggesting BAs could not activate either receptor
in this study.
A general observation in our study is that concentrations of BA as well as the transhepatic BA
ratios differed significantly between rats. Although we were unable to narrow down the underlying
reason for this pronounced animal-to-animal variation, other studies also showed great individual
variation in monkeys and humans [21,31,33,37,38], suggesting that these figures are generally highly
variable between individuals. The mechanisms underlying this inter-individual variability may include
factors such as luminal BA appearance, gut microbiota composition, BA transporter genotypes, BA
synthetic capacity, and gut motility [32]. Moreover, BA concentrations are regulated through a complex
interaction between diet and circadian rhythm [39]. In this study, rats were sacrificed within a rather
narrow time span (10 am and 1 pm) and although not measured, food intake is anticipated to be low
in the hours leading up to the experimental period since the dark period ended at 6 am. Variations
resulting from difference in circadian rhythm and feeding status between study days is therefore
unlikely to have influenced our results to a major extent. Whether a different time of day would have
led to similar or different results is an interesting and potentially important question that requires
further investigation.
A weakness of our study is that the injected CCK only resulted in moderately increased BA
secretion, and it remains to be investigated whether stronger stimuli (e.g., a fat-rich solution) would
have resulted in different or similar hepatic reuptake of the investigated BAs and extra-enterohepatic
plasma concentrations that were more within respective EC50s for FXR/TGR5 activation.
4. Materials and Methods
4.1. Animal Studies
4.1.1. Ethical Considerations
Animal studies were conducted with permission from the Danish Animal Experiments Inspectorate
(2013-15-2934-00833) and approved by the local ethical committee (Department of Experimental
Medicine, University of Copenhagen). Animal studies were conducted in accordance with the EU
Directive 2010/63/EU and guidelines of Danish legislation governing animal experimentation (1987) and
the NIH (publication number 85-23) and were designed to minimize pain or discomfort to the animals.
4.1.2. In Vivo Study
Male Wistar rats were obtained from Janvier (Saint Berthevin Cedex, France) and housed in pairs
under standard conditions with ad libitum access to chow and water and a 12:12 h light and dark
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cycle. Rats were allowed to acclimatize for at least one week before the study. Studies were carried out
between 10 am and 1 pm. Rats were allowed free access to chow and water in the hours leading up to
the experiment, but as the dark period ended at 6 am, the rats can in our experience be considered to
be semi-fasted at study initiation. Rats (mean weight ± standard error of the mean (SEM) = 492 ± 34 g)
were anesthetized with a subcutaneous injection of Hypnorm/midazolam (0.079 mg fentanyl citrate +
2.5 mg fluanisone + 1.25 mg midazolam/mL: 0.3 mL/100 g body weight). The abdominal cavity was
opened and a needle inserted into the inferior caval vein (vena cava inferior) concurrent with insertion
of a non-obstructing plastic catheter into the portal vein. Blood (600 µL/time point) was withdrawn
simultaneously from the two veins into EDTA coated syringes (EDTA: cat. no. 03690, Sigma Aldrich,
Brøndby, Denmark). The samples were immediately transferred into 1.5 mL EDTA-coated tubes (cat.
no. 200 K3E, Microvette; Sarstedt, Nümbrecht, Germany). To prevent clot formation and replace fluid
lost from blood collection, the needle and catheter were both flushed with 400 µL isotonic saline (room
temperature) immediately after sample collections. Samples were drawn at the time points −5, 0, 20,
and 40 min and transferred onto ice and centrifuged (1650× g, 15 min, 4 ◦C) within half an hour of
collection. Supernatant was transferred to fresh centrifuge tubes and immediately stored at −20 ◦C
until analysis as described below. After collection of the zero min sample, sulfated CCK-8 (ammonium
salt, cat. No. 4033010.0001, Bachem, Bubendorf, Schweiz) was injected at a dose of 20 nmol/kg body
weight (~260–550 µL depending of body weight). CCK-8, diluted in isotonic saline supplemented
with 10% (w/v) human serum albumin (cat. No. 12666, Emd Millipore Corp., Bedford, MA, USA) was
injected intravenously through the needle inserted in the inferior caval vein to stimulate bile acid
release into the intestine. In total ~6 mL blood was withdrawn from each animal, corresponding to
~18% of the theoretical total blood volume of 33.2 mL (estimated by: blood volume (mL) = 0.06 × body
weight (g) + 0.77, as described previously [40]).
4.2. Biochemical Measurements
10 µL of plasma was extracted with 80 µL of 87.5% methanol containing 12 pmol of internal
standard. Extracts were clarified by centrifugation (16,100× g, 10 min, 22 ◦C) and dried via speed
vacuum. Quality controls were composed in triplicate at three different concentrations (0.25, 2.5, and
12.5 µM) in the presence of liquid chromatograph mass spectrometry grade water or human plasma.
The quality controls as well as a standard curve were processed in the same manner as samples. A blank
was composed in the presence and absence of human plasma. Quality controls were interspersed
at even intervals throughout the queue. Samples were analyzed in a random order to control for
systematic error. Metabolites were separated, detected, and quantified as described [41]. Briefly,
except for chenodeoxycholic acid (CDCA), BA concentrations were calculated using a standard curve
normalized to internal standards. CDCA was quantified by comparison of its area to the area of the
exogenously added internal standard [42]. The limit of quantification was set as the lowest standard
concentration value that could be distinguished from zero within the standard curve (0.03 µM).
For CDCA, the lowest concentration on the standard curve for DCA was used (0.03 µM). When
corrected for sample dilution the limit of quantification was 0.15 µM. Taurine- and glycine-conjugated
(total conjugated), total non-conjugated, and total BA concentrations were calculated by summing the
appropriate BA concentrations.
4.3. Data Analysis and Statistics
Statistical methods of this study were reviewed by Prof. Jens Juul Holst. Data are presented as
mean concentrations ± SEM. Values below the limit of quantification were imputed using the lowest
standard concentration. BAs whose concentrations were below the limit of quantification in >50% of
samples were excluded from analyses. These BAs were glycochenodeoxycholic acid, glycodeoxycholic
acid, glycoursodeoxycholic acid, lithocholic acid, muricholic acid gamma, taurolithocholic acid, and
tauromuricholic acid gamma Graphs were constructed in GraphPad Prism 6 (La Jolla, CA, USA) and
collected and prepared in Adobe Illustrator (San Jose, CA, USA). Test for statistical significance was
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performed in GraphPad Prism. Significance was assessed at individual time points against own baseline
(average of −5 and 0 min samples, in vena cava inferior and vena portae, respectively) by two-way
ANOVA for repeated measurements followed by Tukey’s multiple comparison test. Significance
amongst relative level of BAs was tested by two-way ANOVA followed by Tukey’s multiple comparison
test, whereas significance between respective AUC’s in v. portae and v. cava inferior was tested by
paired t-test. p ≤ 0.05 was considered significant for all tests. Pearson correlations and significance of
correlation were performed using GraphPad Prism 8 (La Jolla, CA, USA).
5. Conclusions
We find that total BA concentrations in the vena cava inferior were 4–5 times lower than the
total concentration in vena portae. Conjugated BA hepatic reuptake was on average 3–4 times more
efficient than the reuptake of unconjugated BAs, but reuptake varied greatly between individual BAs.
Collectively, BAs that are agonist for FXR/TGR5 were reabsorbed by the liver to the same extent as
non-agonists. The concentration of non-agonists was 2–3-fold higher in vena portae than agonists,
suggesting regulation of extra-enterohepatic FXR/TGR5 activity is mediated by hepatic delivery of BAs
rather than by specific/differential hepatic reuptake of agonistic BAs towards FXR/TGR5.
Supplementary Materials: The following are available online, Figure S1: The major veins involved in bile acid
reabsorption and circulation to the liver as well as sites of blood collection.
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